RGNX is focused on developing, commercializing and licensing recombinant adeno-associated virus gene therapy with a proprietary delivery platform to treat rare diseases. RGNX is commercializing gene therapy products administered directly into the body, or in vivo, based on a NAV Technology Platform. Its NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, Regenxbio said, with exclusive rights to over 100 patents and patent applications worldwide.
September 13, 2021
RegMed Investors’ (RMi) pre-open: the stem, cell and gene therapy sector’s still vulnerable
September 10, 2021
RegMed Investors’ (RMi) closing bell: losses accelerated as the session closed
September 9, 2021
RegMed Investors’ (RMi) closing bell: sentiment loads its soppiness
September 8, 2021
RegMed Investors’ (RMi) closing bell: another cell and gene therapy session of drip, drip down on thin volume
September 7, 2021
RegMed Investors’ (RMi) closing bell: drip, drip down
September 7, 2021
RegMed Investors’ (RMi) pre-open: through looking glass, what does one see?
September 3, 2021
RegMed Investors’ (RMi) closing bell: the cell and gene therapy highs hit the wall and bounced to the downside
September 2, 2021
RegMed Investors’ (RMi) closing bell: strolling to the upside on low volume
September 1, 2021
RegMed Investors’ (RMi) closing bell: are we in a goldilocks continuum?
August 31, 2021
RegMed Investors’ (RMi) closing bell: August floats bye
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.